Cassava Sciences, Inc. Skyrocketed

Tue, Sep 23, 2025 at 07:56 PM

Cassava Sciences, Inc. (SAVA:NASDAQ) rocketted at $3.41, a gain of 47%. On Tue, Sep 23, 2025, SAVA:NASDAQ touched a New 2-Week High of $3.41. The stock got featured on our News Catalysts scanner on Thu, Sep 18, 2025 at 03:04 AM in the 'BIOTECH' category. From Tue, Sep 09, 2025, the stock recorded 50.00% Up Days and 54.55% Green Days

About Cassava Sciences, Inc. (SAVA:NASDAQ)

Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.

Top 10 Gainers:

Super League Enterprise, Inc. (SLE:NASDAQ), 159.45%
Movella Holdings Inc. (MVLA:NASDAQ), 125%
SRAX, Inc. (SRAX:NASDAQ), 105.45%
Innovation Beverage Group Limited (IBG:NASDAQ), 105.07%
Smart for Life, Inc. (SMFL:NASDAQ), 100%
Datavault AI Inc. (DVLT:NASDAQ), 80.07%
Professional Diversity Network, Inc. (IPDN:NASDAQ), 66.43%
STRATA Skin Sciences, Inc. (SSKN:NASDAQ), 52.35%
Cassava Sciences, Inc. (SAVA:NASDAQ), 46.98%
Jiuzi Holdings, Inc. (JZXN:NASDAQ), 44.64%